Complement inhibition alleviates donor brain death-induced liver injury and posttransplant cascade injury by regulating phosphoinositide 3-kinase signaling

Am J Transplant. 2023 Apr;23(4):484-497. doi: 10.1016/j.ajt.2023.01.019. Epub 2023 Feb 4.

Abstract

Brain death (BD) donors are the primary source of donor organs for liver transplantation. However, the effects of BD on donor livers and outcomes after liver transplantation remain unclear. Here, we explored the role of complement and the therapeutic effect of complement inhibition in BD-induced liver injury and posttransplantation injury in a mouse BD and liver transplantation model. For complement inhibition, we used complement receptor 2 (CR2)-Crry, a murine inhibitor of C3 activation that specifically targets sites of complement activation. In the mouse model, BD resulted in complement activation and liver injury in donor livers and a cascade liver injury posttransplantation, mediated in part through the C3a-C3aR (C3a receptor) signaling pathway, which was ameliorated by treatment with CR2-Crry. Treatment of BD donors with CR2-Crry improved graft survival, which was further improved when recipients received an additional dose of CR2-Crry posttransplantation. Mechanistically, we determined that complement inhibition alleviated BD-induced donor liver injury and posttransplant cascade injury by regulating phosphoinositide 3-kinase (PI3K) signaling pathways. Together, BD induced donor liver injury and cascade injury post-transplantation, which was mediated by complement activation products acting on PI3K signaling pathways. Our study provides an experimental basis for developing strategies to improve the survival of BD donor grafts in liver transplantation.

Keywords: PI3K signaling; brain death; cascade injury; complement inhibition; liver transplantation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Brain Death
  • Chemical and Drug Induced Liver Injury, Chronic*
  • Complement System Proteins
  • Humans
  • Liver Transplantation* / adverse effects
  • Living Donors
  • Mice
  • Phosphatidylinositol 3-Kinase
  • Phosphatidylinositol 3-Kinases
  • Recombinant Fusion Proteins
  • Reperfusion Injury*
  • Signal Transduction

Substances

  • Phosphatidylinositol 3-Kinases
  • Phosphatidylinositol 3-Kinase
  • Complement System Proteins
  • CR2-Crry fusion protein, mouse
  • Recombinant Fusion Proteins